Company Encyclopedia
View More
name
Elicio Therapeutics
ELTX.US
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate is ELI-002, a multivalent lymph node–targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trial to target seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node–targeted AMP peptide vaccine in preclinical studies for the treatment of mutant b-raf murine sarcoma viral oncogene homolog B1-driven cancers; and ELI-008, a multivalent lymph node–targeted AMP peptide vaccine in preclinical studies for use in the treatment of mutated tumor protein p53 expressing cancers. Elicio Therapeutics, Inc.
1.936 T
ELTX.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Elicio Therapeutics Grants Stock Options to New Employees

    Elicio Therapeutics Inc. has granted 157,193 inducement stock options to three new employees, allowing them to purchase common stock at $8.52 per share. The options vest over four years, with 25% vesting after the first year and the rest monthly, contingent on continued employment. This announcement was made via GlobeNewswire on December 16, 2025.

    Reuters·
    US
    ELTX
    -1.47%
    Reuters·
    US
    ELTX
    -1.47%

    Elicio Therapeutics Reports Phase 2 Trial Shows ELI-002 7P Induces Broad Immune Response Beyond mKRAS

    Elicio Therapeutics announced interim results from its Phase 2 AMPLIFY-7P trial of ELI-002 7P, showing 87% of patients had T cell responses to tumor neoantigens beyond mKRAS. This suggests ELI-002 7P may broaden immune responses to include personalized tumor antigens. The findings align with previous Phase 1 data and were presented in a recent company announcement.

    Reuters·
    US
    ELTX
    -1.47%
    Reuters·
    US
    ELTX
    -1.47%

    Elicio Therapeutics Names Marc J. Wolfgang as Chief Technology Officer

    Elicio Therapeutics Inc. has appointed Marc J. Wolfgang as Chief Technology Officer. Wolfgang, with over 30 years of experience in biopharmaceutical manufacturing, will aid in advancing Elicio's immunotherapy pipeline and late-stage development efforts. This appointment was announced via GlobeNewswire on November 19, 2025.

    Reuters·
    US
    ELTX
    -1.47%
    Reuters·
    US
    ELTX
    -1.47%

    H.C. Wainwright Sticks to Its Buy Rating for Elicio Therapeutics (ELTX)

    H.C. Wainwright's Robert Burns reiterated a Buy rating for Elicio Therapeutics (ELTX) with a $13.00 price target. Burns, a 2-star analyst with a 0.1% average return, focuses on the Healthcare sector. JonesTrading also maintained a Buy rating with an $18.00 target. The report highlights analyst insights and investment ratings for ELTX.

    Tip Ranks·
    US
    ELTX
    -1.47%
    Tip Ranks·
    US
    ELTX
    -1.47%

    JonesTrading Keeps Their Buy Rating on Elicio Therapeutics (ELTX)

    JonesTrading analyst Soumit Roy maintained a Buy rating on Elicio Therapeutics with a price target of $18.00. Roy, who covers the Healthcare sector, has an average return of -17.3% and a 26.41% success rate. The analyst consensus on Elicio Therapeutics is a Moderate Buy with an average price target of $18.00.

    Tip Ranks·
    US
    ELTX
    -1.47%
    Tip Ranks·
    US
    ELTX
    -1.47%
    © 2025 Longbridge｜Disclaimer